HIGHLIGHTS
- who: Yejing Zhu and colleagues from the China Campania Luigi Vanvitelli China have published the article: Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study, in the Journal: (JOURNAL)
- what: Most of the patients in the study had HBV-related HCC.
- future: Written informed consent was obtained from all patients before treatment initiation which consisted of consent to treatment and the potential use of clinical data in future investigations. The generalization and application of the findings should be done with caution and future prospective . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.